Core Viewpoint - Marubi Biotechnology is seeking a dual listing on the Hong Kong Stock Exchange to enhance its capital strength and international financing capabilities amid increasing competition in the domestic beauty industry and rising online traffic costs, which have led to a situation of revenue growth without profit increase [2][12]. Financial Status - Marubi plans to issue up to 15% of its total share capital as H-shares in its Hong Kong listing [2]. - The company has faced financial scrutiny due to irregularities in financial accounting and has been ordered to rectify these issues by regulatory authorities [2][12]. - As of the end of 2025, Marubi's short-term borrowings amount to approximately 573 million yuan, with total short-term liabilities around 977 million yuan [8][12]. Dividend Policy - Marubi's dividend payout ratio has surged from 37.77% in 2019 to 202.82% in 2023, with a notable payout ratio of 235.87% in 2024 [7]. - The majority of dividends benefit the founding couple, who hold over 80% of the company's shares, raising concerns among investors about the sustainability of such high payouts amid financial pressures [7][9]. Revenue and Profitability - Marubi reported a revenue of 2.97 billion yuan in 2024, with 2.45 billion yuan generated in the first three quarters of 2025 [12]. - Despite revenue growth, net profit growth has slowed, with a mere 2.13% increase in net profit attributable to shareholders in the first three quarters of 2025, while non-recurring net profit declined by 5.42% [12][11]. Marketing and Sales Strategy - The company's marketing expenses have significantly increased, reaching 1.415 billion yuan in the first three quarters of 2025, with a marketing expense ratio of 57.7% [12]. - A high reliance on online sales channels, which accounted for 87.6% of revenue in the same period, has led to increased operational costs due to platform rules and traffic costs [12]. Research and Development - Marubi is transitioning towards a biotechnology-focused beauty company, with an emphasis on research in areas like recombinant collagen [14]. - However, R&D spending has been insufficient, with only a slight increase in R&D expenses compared to a significant rise in sales expenses [16].

Core Viewpoint - Marubi Biotechnology is seeking a dual listing in Hong Kong to enhance its capital strength and international financing capabilities amid increasing competition in the domestic beauty industry and rising online traffic costs, which have led to a situation of revenue growth without profit increase [2][3]. Financial Pressure - Marubi plans to issue up to 15% of its total share capital as H-shares in its Hong Kong listing [3]. - The company reported a net cash outflow of 391 million yuan in Q3 2025, significantly reducing its cash and cash equivalents [5]. - Short-term borrowings reached 573 million yuan, with total short-term liabilities amounting to approximately 977 million yuan [6]. Dividend Policy - Marubi's dividend payout ratio has surged from 37.77% in 2019 to 202.82% in 2023, with a payout ratio of 235.87% in 2024 [10]. - The majority of dividends benefit the founders, who hold over 80% of the shares, raising concerns among investors about the sustainability of high dividends amid financial pressures [10]. Institutional Shareholding - Institutional shareholding has decreased significantly, with the number of shares held by funds dropping from 23.65 million at the end of 2024 to 9.61 million by the end of September 2025 [10][11]. Revenue and Profit Trends - Marubi's revenue grew to 2.97 billion yuan in 2024, with 2.45 billion yuan generated in the first three quarters of 2025 [12]. - However, net profit growth has slowed, with a mere 2.13% increase in net profit attributable to shareholders in the first three quarters of 2025, while non-recurring net profit declined by 5.42% [12]. Marketing Expenses - Marketing expenses for the first three quarters of 2025 reached 1.415 billion yuan, with an expense ratio climbing to 57.7%, primarily due to reliance on online sales channels [12][14]. - The company faced a significant drop in net profit in Q2 2025 despite revenue growth, with sales expense ratios exceeding 60% [14]. Technology Transformation - Marubi officially rebranded to "Marubi Biotechnology" in December 2024, emphasizing its transition to a biotechnology-focused beauty company [18]. - The company has increased its investment in research and development, particularly in recombinant collagen products, which have shown significant market growth potential [18][20]. - However, R&D spending has not kept pace with sales expenses, with only a slight increase in R&D costs compared to a substantial rise in marketing expenses [21].

Core Viewpoint - Marubi Biotechnology is seeking a dual listing in Hong Kong to enhance its capital strength and international financing capabilities, amid concerns over its financial health and high dividend payouts [2][4]. Group 1: Financial Performance and Pressures - Marubi's financial report indicates significant cash flow pressure, with a net cash outflow of 391 million yuan in Q3 2025, leading to a notable decrease in cash and cash equivalents [6]. - The company has short-term borrowings of 573 million yuan and total short-term liabilities of approximately 977 million yuan [8]. - Despite revenue growth, net profit growth has slowed, with a mere 2.13% increase in net profit attributable to shareholders in the first three quarters of 2025, while non-operating profit dropped by 5.42% [16]. Group 2: Dividend Policy and Shareholder Concerns - Marubi's dividend payout ratio has surged from 37.77% in 2019 to 202.82% in 2023, with a staggering 235.87% payout ratio in 2024, raising concerns among investors about the sustainability of such high dividends amid financial pressures [11]. - The majority of dividends benefit the founding couple, who hold over 80% of the shares, leading to investor worries about the prioritization of dividends over business reinvestment [11]. Group 3: Market Position and Competition - The competitive landscape in the domestic beauty industry is intensifying, with rising online traffic costs contributing to Marubi's struggle to increase profitability despite revenue growth [2]. - The company's reliance on online sales channels, which accounted for 87.6% of revenue in the first three quarters of 2025, has made it vulnerable to platform rules and rising costs [18]. Group 4: Technological Transformation and R&D Investment - Marubi is transitioning towards a biotechnology-focused beauty company, with significant investments in research and development, particularly in recombinant collagen products [20]. - However, R&D spending has not kept pace with sales expenses, with only a slight increase in R&D costs compared to a substantial rise in marketing expenses, indicating a potential imbalance in investment strategy [22].